Novel Therapeutic Approach for Human T-cell Malignancies

Istituto Oncologico Veneto IRCCS

Status: Enrolling

Conditions: T-Cell Leukemia/Lymphoma, Adult

Treatments: Other: Translation analysis

Study type: Observational

Funder types: Other

Identifiers

NCT06600568

ROSinTALL

Details and patient eligibility

About

This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.

Interactions between drugs capable of activating the apoptotic process (e.g., Venetoclax) and drugs capable of altering ROS homeostasis (e.g., inhibitors of the enzyme glucose-6-phosphate dehydrogenase) will be examined.

The most promising compounds will be selected based on results obtained in vitro on cell lines and PDX already available in the laboratory, and then will be assayed ex vivo in cells obtained from patients with resistant/refractory T-cell neoplasms.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with pre- and post-thymic T-cell leukemia/lymphoma
• Patients of both sexes
• Age of patients older than 18 years
• Patient is willing to provide written and signed informed consent for participation in the study

Exclusion criteria

-Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.